Trial
NCT02336425
Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Asthma
Intervention
QGE031
Why stopped
This study was terminated due to the efficacy results from an interim analysis (at the end of treatment epoch) of the Phase II study CQGE031B2201 (NCT01716754).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-08-11